Repligen stock
RGENNASDAQRepligen Corporation, HealthcareISIN US7599161095
51Score 51 out of 100, Neutral
Price and trend
69 / 100
Price history
+13% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 11% below its 52-week high. Largest decline in 20 years: 68% (September 2021 to May 2026).
Chart figures for advanced users
- SMA 50$177.31
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$145.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$102.87
- The lowest closing price of the last twelve months.
- Resistance$194.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Repligen Corporation belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $11.03B, is number 15 of 44 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $846.27M (up 14.6%) and adjusted earnings per share of $2.07 (up 21.2%).
- MEQIRI Score 51 out of 100 (Neutral): rank 374 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $110.58, with the price 56% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 23.9% a year through 2028 (estimates from 10 analysts).Growth 59
- Growing faster than its industryRevenue up 15% a year since 2020, Medical (Instruments & Supplies) median 9.5%.Growth 59
- More cash than debtCash $862.98M, financial debt $692.24M.Stability 67
Weaknesses
- Margin fallingOperating margin 8.1%, average of the prior years 22.2% (to 2024).Profitability 24
- Loss-makingLoss of $11.8M over the last 12 months.Fundamentals 65
- Volatile share priceVolatility 47% a year over the last 12 months.Stability 67
Its standout strength is momentum, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $78.99 and expensive above $184.31 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $89.83, at 7.8% it would be $141.92.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.8% on the twelve months before. Revenue has grown strongly since 2005, at around 24% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 47%, operating 8%, net 7%. Last 12 months: net −1%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 27 Oct 2026EPS reported $0.53 (expected $0.46)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.07+0.5%
- Revenue
- $846.27M+2.1%
- Earnings per share
- $2.66+0.6%
- Revenue
- $1.06B+8.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.5%Repligen raised its full year 2026 guidance: revenue now 844 to 852 million (midpoint 848 million), organic growth to 12 to 13% from a lower prior range, operating margin to 16 to 16.3%, and earnings per share to 2.05 to 2.09 dollars, helped by the BioLife acquisition.
“We are raising our adjusted operating income guidance to a range of $135 to $139 million and our adjusted operating margin guidance to 16% to 16.3%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $4.54M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Loeillot OlivierSale
5 Oct 2026, Chief Executive Officer
- Shares
- 5,535
- Price
- $187.29
- Value
- $1.04M
- Loeillot OlivierSale
24 Sept 2026, Chief Executive Officer
- Shares
- 4,542
- Price
- $190.00
- Value
- $862,980
- Loeillot OlivierSale
21 Sept 2026, Chief Executive Officer
- Shares
- 5,426
- Price
- $180.00
- Value
- $976,680
Show 4 more
- Loeillot OlivierSale
4 Sept 2026, Chief Executive Officer
- Shares
- 3,035
- Price
- $165.90
- Value
- $503,507
- Loeillot OlivierSale
20 Aug 2026, Chief Executive Officer
- Shares
- 5,426
- Price
- $180.00
- Value
- $976,680
- Garland Jason KSale
16 Jul 2026, CFO
- Shares
- 530
- Price
- $150.00
- Value
- $79,500
- Garland Jason KSale
25 Jun 2026, CFO
- Shares
- 733
- Price
- $145.00
- Value
- $106,285
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Repligen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 51
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- ColoplastCOLO-B.CO $16.54B69
- SolventumSOLV $15.06B61
- Baxter InternationalBAX $13.63B47
- Cooper CompaniesCOO $11.97B61
- AvantorAVTR $10.66B53
- AptarGroupATR $9.07B65
- Bausch + LombBLCO $7.62B50
- Asahi Intecc7747.T $6.34B83
ETFs that hold Repligen
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.87% | 0.40% | €1.49B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.32% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.21% | 0.43% | €2.48B |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.18% | 0.35% | €434.1M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.09% | 0.35% | €8.19B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €944.34M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.03% | 0.25% | €175.89M |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.01% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.